title: [Cartilage repair and regenerative medicine ; past, present, and future].
abstract: Since the days of ancient Greece, it has been known that articular cartilage has poor potential to repair. In April, 2013, autologous chondrocyte implantation (ACI) was approved by the Japanese ministry of Health, Labour and Welfare, as the first orthopedic cell therapy in Japan. Half a century has passed since Chesterman's report on rabbit allogeneic chondrocyte implantation, and approximately 20 years since the first human ACI report by Brittberg. In Japan, 24 years has passed since Wakitani's allogeneic chondrocyte implantation, and over 10 years since the human ACI report by Ochi. A long-term follow-up clinical trial with the high statistical power is needed to verify the safety and efficacy of new cartilage joint therapy. Moreover, we need the infrastructure, including drug and/or device regulation and timely approved by the government, to apply new therapies in similar time frames to other developed nations.
authors.affiliation: Department of Health and Sports Sciences, Mukogawa Women's University, Nishinomiya, Japan.
authors.forename: Hisashi
authors.initials: H
authors.lastname: Mera
authors.forename: Maki
authors.initials: M
authors.lastname: Itokazu
authors.forename: Shigeyuki
authors.initials: S
authors.lastname: Wakitani
mesh_terms: D000818:Animals; D002356:Cartilage; D002357:Cartilage Diseases / Q000628:therapy*; D002358:Cartilage, Articular; D064987:Cell- and Tissue-Based Therapy; D019902:Chondrocytes / Q000637:transplantation*; D004195:Disease Models, Animal; D006801:Humans; D019637:Orthopedic Procedures / Q000379:methods / Q000639:trends; D011817:Rabbits; D016032:Randomized Controlled Trials as Topic; D044968:Regenerative Medicine / Q000379:methods* / Q000639:trends*; D014182:Transplantation, Autologous